Clinical trials: Influenza Type A
Systemic Lupus, Sjogren's Syndrome
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
Studies in the literature have shown reduced effectiveness of influenza A (H3N2) virus vaccine (20-40%) when compared to A (H1N1) and influenza B.
- Trial name
- NCT03540823
- Testing
- Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
- Where
- Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Influenza A Subtype H5N1 Infection
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the…
- Trial name
- HIPCVAX-010S (NCT03701061)
- Testing
- Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Swine-Origin Influenza A H1N1 Virus
Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine
This is to evaluate safety of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese subjects.
- Trial name
- NCT01098786
- Testing
- Cell-derived A/H1N1 influenza HA vaccine
- Where
- Japan
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Novel Influenza A, H1N1
Novel Influenza A (H1N1) Surveillance Registry
The demographic characteristics, clinical features, course, and outcomes of severe H1N1 influenza infection requiring intensive care have not been defined rigorously and systematically.
- Conditions
- Novel Influenza A, H1N1, Influenza
- Trial name
- NCT01046331
- Where
- 86 sites in United States
- Volunteers
- 894 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Influenza
Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
To assess whether CAIV-T was transmitted from vaccinated children to their unvaccinated contacts in a day care setting; and if so, to estimate the rate of transmission.
- Trial name
- NCT00192361
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Immune Response to Influenza Vaccine, Influenza A Virus Infection
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
The purpose of this study is to assess the serologic and cell-mediated immune response to licensed live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children 5-17 years old.
- Conditions
- Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
- Trial name
- NCT02250274
- Testing
- LAIV, IIV
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Marshfield Clinic Research Foundation
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT01040078
- Testing
- 7.5ug H1N1 Influenza vaccine, 15ug H1N1 vaccine, seasonal influenza vaccine
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Influenza
Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine.
- Trial name
- NCT00944073
- Testing
- Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
- Where
- 9 sites in United States
- Volunteers
- 583 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers…
- Trial name
- NCT00192283
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 2,903 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Cystic Fibrosis With Gastrointestinal Manifestation
Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination
Multicenter prospective cohort of approximately 1000 cystic fibrosis patients followed in the Ile de France during the 2009-2010 influenza season with the main objective to assess the effectiveness of antiviral vaccination…
- Trial name
- MUCOFLU (NCT01499914)
- Testing
- influenza vaccination
- Where
- France
- Volunteers
- 439 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Virus Diseases, Respiratory Tract Diseases
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
The primary safety objective of this study is to assess the safety of split- virion inactivated H1N1 vaccine with and without adjuvant when administered at the 7.5,15 or 30 mcg dose.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT00975572
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 30 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Swine Flu (Novel Influenza A H1N1) Vaccine Study
In the first half of this year a novel Influenza A H1N1 virus has resulted in an influenza pandemic. The United Kingdom has seen a particularly high incidence of disease.
- Trial name
- NCT00980850
- Testing
- Baxter Novel Influenza A H1N1 Whole Virus Vaccine, GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza A, Influenza B
Covid Flu A/B and RSV 4 in 1 Diagnostic Test
The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection.
- Conditions
- Influenza A, Influenza B, COVID - 19, RSV
- Trial name
- NCT07308158
- Testing
- Investigational Flu A/B Covid-19 and RSV Diagnostic Test
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 1,119 people
- Sponsor
- iHealth Labs inc
Healthy
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of(CAIV-T) in Healthy Children.
- Trial name
- NCT00192374
- Testing
- CAIV-T, Liquid
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 1,920 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Prospective Study of AI H5N1 in China
The purpose of this study is to see if people in China who have contact with someone infected with bird flu (H5N1) become infected themselves without necessarily getting sick.
- Trial name
- NCT00428493
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)